Lomefloxacin - oral


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Acute bacterial exacerbations of chronic bronchitis 400 mg once daily for 10 days. Surgical prophylaxis 400 mg as a single dose 1-6 hr pre-op. Uncomplicated UTI 400 mg once daily. Treament duration depends on bacterial strains: E. coli: 3 days. K. pneumoniae, P. mirabilis or S. saprophyticus : 10 days. Complicated UTI 400 mg once daily for 14 days. Otic Otitis externa; Otitis media As .3% soln: Use as diected. Ophth Bacterial conjunctivitis As 0.3% soln: Use as directed.
Dosage Details
Ophthalmic
Bacterial conjunctivitis
Adult: Instil 0.3% solution into the affected eye/s.

Oral
Acute bacterial exacerbation of chronic bronchitis
Adult: 400 mg once daily for 10 days.

Oral
Prophylaxis of surgical infections
Adult: 400 mg as a single dose 1-6 hr before procedure.

Oral
Complicated urinary tract infections
Adult: Due to E. coli, K. pneumoniae, P. mirabilis or P. aeruginosa: 400 mg once daily for 14 successive days.

Oral
Uncomplicated urinary tract infections
Adult: 400 mg once daily. Due to E. coli: For 3 successive days. Due to K. pneumoniae, P. mirabilis or S. saprophyticus: For 10 successive days.

Otic/Aural
Otitis externa, Otitis media
Adult: Instil 0.3% solution into the affected ear/s.
Renal Impairment
Oral:
Acute bacterial exacerbation of chronic bronchitis: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.
CrClDosage
10-40Initially, 400 mg daily. Maintenance: 200 mg daily.
Complicated urinary tract infections: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.
CrClDosage
10-40Initially, 400 mg daily. Maintenance: 200 mg daily.
Uncomplicated urinary tract infections: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.
CrClDosage
10-40Initially, 400 mg daily. Maintenance: 200 mg daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to the drug or other quinolones; children <18 yr; pregnancy and lactation.
Special Precautions
Avoid prolonged exposure to sunlight or artificial UV light. Known or suspected CNS disorders e.g. severe cerebral arteriosclerosis, epilepsy or other factors that predispose to seizures. Avoid in patients with known QT prolongation, uncorrected hypokalaemia. May impair ability to drive or operate machinery. Renal impairment.
Adverse Reactions
Nausea, abdominal pain or discomfort, diarrhoea; headache, dizziness, insomnia; rash, pruritus, photosensitivity; thrombocytopenia.
Potentially Fatal: Anaphylactic or anaphylactoid reactions.
Overdosage
Empty the stomach by inducing vomiting or by gastric lavage. Treatment is supportive. Maintain adequate hydration. Haemodialysis or peritoneal dialysis is unlikely to be helpful.
Drug Interactions
Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.
Potentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.
Action
Description: Lomefloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
Pharmacokinetics:
Absorption: Rapid and complete from the GI tract (oral); peak plasma concentrations after 1-1.5 hr. Absorption delayed with food.
Distribution: Widely distributed; lungs and prostate. Protein-binding: 10%.
Excretion: Via urine (as unchanged drug and small amounts of glucuronide metabolites); may be prolonged in renal impairment. Via faeces (small amounts as unchanged drug); 7-8 hr (elimination half-life).
Storage
Oral:
Acute bacterial exacerbation of chronic bronchitis: Store at 15-25°C (59-77°F).
Prophylaxis of surgical infections: Store at 15-25°C (59-77°F).
Uncomplicated urinary tract infections: Store at 15-25°C (59-77°F).
Disclaimer: This information is independently developed by MIMS based on Lomefloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Lomflox
  • Okacin
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in